The Bruton tyrosine kinase (<scp>BTK</scp>) inhibitor <scp>PCI</scp>‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (<scp>DLBCL</scp>) and mantle cell lymphoma (<scp>MCL</scp>) cells sensitive or resistant to bortezomib

Girija Dasmahapatra(Virginia Commonwealth University), Steven Grant(Virginia Commonwealth University)

British Journal of Haematology

January 30, 2013

10.1111/bjh.12206

Cited by 84

Related Papers

Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation

|Journal of Biological Chemistry|2005|284

Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma

|Clinical Cancer Research|2009|230

Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms

|Blood|2004|123

HDAC Inhibitors Potentiate the Activity of the BCR/ABL Kinase Inhibitor KW-2449 in Imatinib-Sensitive or -Resistant BCR/ABL+ Leukemia Cells <i>In Vitro</i> and <i>In Vivo</i>

|Clinical Cancer Research|2011|76

Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation

|Blood|2007|73